A Study of Rituximab in Frontline Therapy for Glomerulonephritis

Status Recruiting

Clinical Trial Summary

This study included patients with glomerulonephritis who planned to receive rituximab treatment, and observed the efficacy and safety of rituximab in different glomerulonephritis in the real world. According to the pathological types of glomerulonephritis, they were divided into two cohorts : membranous nephropathy ( MN ) group or minimal change disease / focal segmental glomerulosclerosis ( MCD / FSGS ) group.

Clinical Trial Description

A total of 100 patients with glomerulonephritis who planned to receive rituximab treatment were enrolled in the study. According to the pathological types of glomerulonephritis, they were divided into MN cohort and MCD / FSGS cohort, with 50 patients in each cohort. All eligible patients who meet the inclusion and exclusion criteria will be invited to participate in this study. ;

Study Design

Related Conditions & MeSH terms

Glomerulonephritis

Clinical Trial Details

NCT number	NCT05761938
Study type	Observational
Source	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact	GENGRU JIANG, doctor
Phone	+86-13816238339
Email	jianggengru@xinhuamed.com.cn
Status	Recruiting
Phase
Start date	February 1, 2023
Completion date	December 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00001457` - Lamivudine for Chronic Hepatitis B	Phase 2
Recruiting	`NCT05505955` - Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency	Phase 1
Recruiting	`NCT01240564` - The Nephrotic Syndrome Study Network (NEPTUNE)	N/A
Active, not recruiting	`NCT05174221` - A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy	Phase 1
Completed	`NCT00426348` - A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy	Phase 4
Recruiting	`NCT04662723` - Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.	Phase 4
Completed	`NCT02700516` - Recurrent Glomerulonephritis After Renal Transplantation	N/A
Recruiting	`NCT00862693` - Calcitriol in the Treatment of Immunoglobulin A Nephropathy	Phase 4
Completed	`NCT00983034` - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy	N/A
Completed	`NCT00004990` - Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis	Phase 2
Recruiting	`NCT04846010` - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2	Phase 1/Phase 2
Terminated	`NCT04387448` - A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease	Phase 2
Terminated	`NCT04950114` - An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases	Phase 2
Completed	`NCT00437463` - Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor	Phase 3
Terminated	`NCT02523768` - Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment	Phase 4
Completed	`NCT00106561` - Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney	Phase 2/Phase 3
Completed	`NCT04733040` - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)	Phase 2
Completed	`NCT00001676` - Cyclophosphamide and Fludarabine to Treat Lupus Nephritis	Phase 1
Recruiting	`NCT02063100` - Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis	Phase 4
Completed	`NCT01093157` - A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy	Phase 1/Phase 2